Bill Sponsor Says Prospects 'Pretty Good' for Patent-Reform Legislation to Pass This Year | GenomeWeb

This article was originally published on June 12.

WASHINGTON, DC – The prospects are "pretty good" for enactment of a US patent reform bill that has passed Senate and House review committees but for months has been heavily contested by the biotech, pharmaceutical, and university communities, Senator Arlen Specter, who is a co-sponsor of the bill, said today.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.